Transforming The Future of Cancer Detection with Biomarker Blood Tests

Transforming the Future of Cancer Detection

Cizzle Bio is driving a new era in cancer diagnostics, empowering patients and physicians with early-detection biomarker blood tests for cancer developed by the world’s leading experts. Our innovative solutions, CIZ1B for lung cancer and DEX-G2 for gastric cancer, are leading-edge breakthroughs in minimally invasive, highly accurate diagnostics for two of the world’s deadliest cancers.

Early-detection biomarker blood tests for cancer developed by the world’s leading experts.

Lung Cancer
Gastric Cancer 
PROBLEM

Detect Early. Save Lives.

Cancer is one of the leading causes of death worldwide, and late detection drastically reduces survival rates. The need for accurate, cost-effective, early-detection tools has never been more urgent.

LUNG CANCER
0

Nearly 5,000 lives are lost daily, with 75% of cases diagnosed at advanced stages, when treatment options are limited, and survival rates are low. 1

GASTRIC CANCER
0

Every day, 2,100 people around the world lose their lives to gastric cancer, the third most lethal cancer globally. 2

EARLY DETECTION IS KEY

Identifying cancer at its earliest stages significantly improves survival rates, giving patients hope for a better future.

The Urgency of Early Detection

Both lung and gastric cancers are known for their silent progression, often remaining undetected until late stages when treatment options are limited. While early detection is vital to improve cancer survival, only a fraction of high-risk individuals receive routine testing.

LUNG CANCER
SCREENING RATES

Fewer than 6% of the 14.2 million Americans recommended for annual screening undergo testing, leaving millions undiagnosed. 3

GASTRIC CANCER

Conventional methods like endoscopy are invasive and resource-intensive, limiting their widespread use.

SOLUTION

Revolutionary Biomarker Blood Tests

Cizzle Bio leverages cutting-edge biomarker technology to provide minimally invasive, highly accurate blood tests for early cancer detection.

CIZ1B

Biomarker Test for Early Detection of Lung Cancer

  • Sensitivity of 95% for Stage I Detection and Negative Predictive Value (NPV) at 96%. 4
  • A minimally invasive, cost-effective tool that minimizes need for repeated CT scans—reducing false positives, unnecessary follow-ups, and radiation exposure.

Learn more

DEX-G2

Biomarker Test for Early Detection of Gastric Cancer

  • Sensitivity of 95% and specificity of 97% for early-stage gastric cancer detection. 5
  • Innovative dual-action mechanism combining cell-free and exosomal miRNAs for unmatched precision.
  • Minimally invasive and accessible, addressing key limitations of traditional endoscopy.

Learn more

Partnering with Industry Leaders

In collaborating with industry leaders like Moffitt Cancer Center and BBI Solutions, our work is driven by trusted partnerships and cutting-edge research. Together, we’re integrating minimally invasive biomarker blood tests into mainstream healthcare.

Saving Lives, One Test at a Time

At Cizzle Bio, our driving purpose—Detect Early. Save Lives.—inspires every breakthrough we deliver. By giving patients the power of early action and equipping physicians with precision diagnostics, we’re changing the course of cancer care and saving more lives.

FOR PATIENTS

Take proactive steps.

Learn how to get tested.

Learn More

Lung Cancer Test
Gastric Cancer Test 
FOR PHYSICIANS

Learn more about how to access our CIZ1B and DEX-G2 biomarker tests.

Learn More

Lung Cancer Test
Gastric Cancer Test

Join us in the fight against cancer.

Help us change these dire statistics. Stay informed and support advancements in cancer diagnostics. Subscribe for updates.

References:

  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249.)

  • Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209-249

  • American Lung Association. (2024). State of lung cancer: Key findings. Retrieved October 26, 2025, from https://www.lung.org/research/state-of-lung-cancer/key-findings

  • Coverley D, Higgins G, West D, et al. A quantitative immunoassay for the lung-cancer biomarker CIZ1b in patient plasma. Clin Biochem. 2017;50(6):336-343.

  • https://jamanetwork.com/journals/jamasurgery/fullarticle/2837074